### Fiscal Year 2012 (FY12) Prostate Cancer Research Program (PCRP)
#### Reference Table of Award Mechanisms and Submission Requirements

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| **(New for FY12!)** Biomarker Development Award** | Independent investigators at or above the level of Assistant Professor (or equivalent) | - Preproposal is required; application submission is by invitation only.  
- Supports high-impact research aimed at qualifying or validating biomarkers for rapid transfer to clinical practice for prostate cancer.  
- Projects studying multiple biomarkers are highly encouraged.  
- Multi-institutional efforts are highly encouraged.  
- Presentation of preliminary data demonstrating the suitability of the biomarker(s) for further testing toward clinical application is required.  
- PIs must demonstrate availability and accessibility of samples and/or data, and are encouraged to leverage pre-existing resources, e.g., biospecimen banks  
- Studies are expected to be initiated within 6 months of the award date. | Maximum funding of $2.25M for direct costs (plus indirect costs)  
- Maximum period of performance is 3 years | Pre-application (Preproposal): May 3, 2012  
5:00 p.m. Eastern Time  
Application: August 23, 2012  
11:59 p.m. Eastern Time |

| **(New for FY12!)** Clinical Exploration Award** | Independent investigators at or above the level of Assistant Professor (or equivalent) | - Preproposal is required; application submission is by invitation only.  
- Supports rapid execution of hypothesis-driven, early phase clinical trials or studies correlative to existing clinical trials to examine interventions that could have a major impact on prostate cancer clinical management. It is anticipated that proposed studies will explore innovative and untested concepts to provide scientific rationale or initial proof-of-principle for larger clinical trials in prostate cancer.  
- Interventions may include drugs, devices, biologics, surgical procedures, behavior modifications, or other.  
- Investigational New Drug or Investigational Device Exemption approvals, if applicable, must be in place before submission of the application.  
- Clinical trials are expected to be initiated within 12 months of the award date. | Maximum funding of $450K for direct costs (plus indirect costs)  
- Maximum period of performance is 3 years | Pre-application (Preproposal): May 3, 2012  
5:00 p.m. Eastern Time  
Application: August 23, 2012  
11:59 p.m. Eastern Time |

Grants.gov Funding Opportunity Number: W81XWH-12-PCRP-BDA  
Grants.gov Funding Opportunity Number: W81XWH-12-PCRP-CEA
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Health Disparity Research Award (Modified!) | **Established Investigators:** Independent investigators at or above the level of Assistant Professor (or equivalent); **or** New Investigators: Investigators that meet the following criteria at the application submission deadline date:  
  - Have the freedom to pursue individual aims without formal mentorship  
  - Have not previously received a PCRP Health Disparity Research Award  
  - Have either completed at least 3 years of postdoctoral training or fellowship or are within 5 years of having begun first independent faculty position (or equivalent) | **Supports new ideas based on innovative concepts or methodologies for prostate cancer disparity research that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality.**  
  - Preliminary data are encouraged, but not required.  
  **Qualified Collaborator Option** supports a higher level of funding for PIs who include a collaborator that significantly contributes to the research project such that it could not otherwise be accomplished and contributes a minimum 10% level of effort to the project.  
  **New Investigator Option** supports applicants early in their faculty appointments or in the process of developing independent research careers.  
  **Nested Traineeship Option** supports predoctoral or postdoctoral training for individuals committed to pursuing careers as independent investigators in prostate cancer health disparity research.  
  - Does not support clinical trials. | **Maximum funding of $450K for direct costs (plus indirect costs)**  
  - If applying for the Qualified Collaborator Option, maximum funding of $600K for direct costs (plus indirect costs)  
  - Maximum period of performance is 3 years  
  - Additional funds can be requested if including the Nested Traineeship Option | Pre-application (Letter of Intent):  
  July 26, 2012  
  5:00 p.m. Eastern Time  
  Application:  
  August 9, 2012  
  11:59 p.m. Eastern Time  
  Confidential Letters of Recommendation (Nested Traineeship Option only):  
  August 9, 2012  
  5:00 p.m. Eastern Time |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Laboratory - Clinical Transition Award (Modified!) | Independent investigators at or above the level of Assistant Professor (or equivalent) | • Preproposal is required; application submission is by invitation only.  
• Supports product-driven preclinical studies of promising novel lead agents or medical devices that have the potential to revolutionize prostate cancer clinical care.  
• For lead agents, PIs are expected to demonstrate within the application (1) a validated target, (2) access to either one lead agent or a limited number of lead agents for optimization, and (3) the agent’s mechanism of action.  
• For lead agents, preliminary data should demonstrate validated target availability and distribution in relevant human tissues and substantive information from model systems that supports potential efficacy of the lead agent(s) in humans.  
• For medical devices preliminary data should demonstrate reliability, reproducibility and effectiveness for the medical device.  
• Supports research that ranges from preclinical study through cGMP production. | Maximum funding of $1.5M for direct costs (plus indirect costs)  
Maximum period of performance is 3 years | Pre-application (Preproposal): May 3, 2012  
5:00 p.m. Eastern Time  
Application: August 23, 2012  
11:59 p.m. Eastern Time |
| Transformative Impact Award (New for FY12!) | Independent investigators at or above the level of Assistant Professor (or equivalent) | • Preproposal is required; application submission is by invitation only.  
• Supports prostate cancer research efforts with near-term, transformative impact for prostate cancer patients.  
• Research efforts based on team science are expected, with support by a PI with a demonstrated record of successfully leading large, focused projects.  
• Consistent with the goal of near-term benefit for patients, the scope of the research effort must include translational studies, clinical research, and/or clinical trials.  
• Applicants must demonstrate that they are prepared to initiate the study immediately upon receiving the award (i.e., as of the award date). | Maximum funding of $6.0M for direct costs (plus indirect costs)  
Maximum period of performance is 3 years | Pre-application (Preproposal): May 3, 2012  
5:00 p.m. Eastern Time  
Application: August 23, 2012  
11:59 p.m. Eastern Time |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| **Exploration - Hypothesis Development Award** | Investigators at or above the level of postdoctoral fellow (or equivalent)                      | • Supports the exploration of highly innovative, untested, potentially groundbreaking concepts in prostate cancer.  
• Emphasis is on innovation; potential impact may be difficult to predict.  
• Human subject studies are permitted provided the studies are exempt or eligible for expedited review.  
• Preliminary data are strongly discouraged.  
• *Peer and programmatic reviewers are blinded to the identities of the PI, collaborators, and their institutions.* | • Maximum funding of $75K for direct costs (plus indirect costs)  
• Maximum period of performance is 1 year | Pre-application (Letter of Intent):  
June 6, 2012  
5:00 p.m. Eastern Time  
Application:  
June 20, 2012  
11:59 p.m. Eastern Time |
| **Idea Development Award**                    |                                                                                                 |                                                                                        |                                                                                                |                                         |
| Establishing Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent); or New Investigators: Investigators that meet the following criteria at the application submission deadline date:  
• Have the freedom to pursue individual aims without formal mentorship  
• Have not previously received a PCRP Idea Development Award  
• Have either completed at least 3 years of postdoctoral training or fellowship or are within 5 years of having begun first independent faculty position (or equivalent) |  
• Preproposal is required; application submission is by invitation only.  
• Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research, and have the potential to make an important contribution to eliminating death and suffering from prostate cancer.  
• Preliminary data are encouraged but not required.  
• Innovation and Impact are the most important review criteria.  
• Does not support clinical trials.  
• *New Investigator Option* supports applicants early in their faculty appointments or in the process of developing independent research careers. |  
Established PIs:  
• Maximum funding of $375K for direct costs (plus indirect costs)  
New Investigator Option:  
• Maximum funding of $225K for direct costs (plus indirect costs)  
• Maximum period of performance is 3 years | Pre-application (Preproposal):  
April 24, 2012  
5:00 p.m. Eastern Time  
Application:  
August 9, 2012  
11:59 p.m. Eastern Time |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Synergistic Idea Development Award | Independent investigators at or above the level of Assistant Professor (or equivalent) | • Preproposal is required; application submission is by invitation only.  
• Supports new or existing partnerships between two or three independent investigators to address a central innovative question or problem in prostate cancer that may include high risk, provided there is a potential for significant impact.  
• Preliminary data are encouraged but not required.  
• Synergy, Innovation, and Impact are the most important review criteria.  
• Does not support clinical trials. | • Maximum funding of $750K for direct costs (plus indirect costs)  
• Maximum period of performance is 3 years | Pre-application (Preproposal):  
May 3, 2012  
5:00 p.m. Eastern Time  
Application:  
August 9, 2012  
11:59 p.m. Eastern Time |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| **Collaborative Undergraduate Historically Black Colleges and Universities (HBCU) Student Summer Training Program Award** | Independent investigators at or above the level of Assistant Professor (or equivalent) with a proven record in prostate cancer research and training | - Supports new or existing summer training programs for undergraduate HBCU students at host institutions with thriving prostate cancer research programs.  
- Must enroll a minimum of four undergraduate HBCU trainees per year.  
- Host institution must have a record of achievement in prostate cancer research and training. | Maximum funding of **$185K** for direct costs (plus indirect costs)  
- Maximum period of performance is 3 years | Pre-application (Letter of Intent):  
June 6, 2012  
5:00 p.m. Eastern Time  
Application:  
June 20, 2012  
11:59 p.m. Eastern Time |
| **Physician Research Training Award** | At the time of application submission, the PI must be either:  
- In the last year of an accredited medical residency or medical fellowship program; or  
- Within 3 years of having initiated an appointment as Instructor, Assistant Professor, or equivalent | - Supports training of physicians with clinical duties for careers in prostate cancer research.  
- PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.  
- PIs must have a designated mentor with an established research program in prostate cancer.  
- Institutions must provide at least 40% protection of PI’s time for research.  
- Projects that focus on providing training in basic research are highly encouraged. | Maximum funding of **$520K** ($130K per year) for direct costs (plus indirect costs)  
- Maximum period of performance is 4 years | Pre-application (Letter of Intent):  
June 6, 2012  
5:00 p.m. Eastern Time  
Confidential Letters of Recommendation:  
June 20, 2012  
5:00 p.m. Eastern Time  
Application:  
June 20, 2012  
11:59 p.m. Eastern Time |
| **Postdoctoral Training Award** | By December 31, 2012, the PI must:  
- Have successfully defended a doctoral thesis or posses an M.D. degree (or equivalent)  
- Have 3 years or less of postdoctoral fellowship experience | - Supports prostate cancer research training opportunities for postdoctoral trainees who are recent doctoral graduates.  
- PIs must have a designated mentor who is an experienced prostate cancer researcher. | Maximum of **$115K** ($57.5K per year) for direct costs (plus indirect costs up to a maximum rate of 8%)  
- Maximum period of performance is 2 years | Pre-application (Letter of Intent):  
June 6, 2012  
5:00 p.m. Eastern Time  
Confidential Letters of Recommendation:  
June 20, 2012  
5:00 p.m. Eastern Time  
Application:  
June 20, 2012  
11:59 p.m. Eastern Time |